David Stamler
Chief Executive Officer presso ALTERITY THERAPEUTICS LIMITED
Profilo
David A.
Stamler is currently the Chief Executive Officer at Alterity Therapeutics Ltd.
He previously held positions as the Director-Clinical Research at Abbott Laboratories from 1993 to 1997, Vice President-Clinical Development & Therapeutic at Teva Pharmaceutical Industries Ltd.
from 2015 to 2017, Senior Global Project Leader-CNS Diseases at Fujisawa Pharmaceutical Co., Ltd.
from 2003 to 2005, Chief Scientific Officer & Head-Drug Development at Prestwick Pharmaceuticals, Inc. from 2005 to 2008, Chief Medical Officer & Senior Vice President at XenoPort, Inc. from 2008 to 2010, Vice President-Research & Development at Fujisawa Healthcare, Inc. from 1997 to 2005, Vice President- Clinical Research Center at Astellas Research Institute of America LLC from 2000 to 2003, and Chief Medical Officer at Auspex Pharmaceuticals, Inc. from 2011 to 2015.
Dr. Stamler completed his undergraduate degree at The University of Chicago and obtained a doctorate from Pritzker School of Medicine.
Posizioni attive di David Stamler
| Società | Posizione | Inizio |
|---|---|---|
| ALTERITY THERAPEUTICS LIMITED | Chief Executive Officer | 07/01/2021 |
Precedenti posizioni note di David Stamler
| Società | Posizione | Fine |
|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01/01/2017 |
| AUSPEX PHARMACEUTICALS INC | Chief Tech/Sci/R&D Officer | 05/05/2015 |
| XENOPORT, INC. | Chief Tech/Sci/R&D Officer | 19/11/2010 |
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Chief Tech/Sci/R&D Officer | 01/01/2008 |
Fujisawa Pharmaceutical Co., Ltd.
 Fujisawa Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Fujisawa Pharmaceutical Co. Ltd. develops, manufactures and markets pharmaceuticals and medical products. The Group's principal activity is the manufacture and sale of pharmaceuticals, medical equipment and supplies, home care products, chemicals and animal health products. Pharmaceuticals (ethical drugs, OTC drugs, toilet goods) accounted for 91% of fiscal 2002 revenues and other operations (food additives, industrial chemicals, animal drugs, research and clinical reagents). It was founded in 1894 and was headquartered in Osaka, JP | Corporate Officer/Principal | 01/01/2005 |
Formazione di David Stamler
| The University of Chicago | Undergraduate Degree |
| Pritzker School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| ALTERITY THERAPEUTICS LIMITED | Health Technology |
| Aziende private | 6 |
|---|---|
Fujisawa Pharmaceutical Co., Ltd.
Fujisawa Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Fujisawa Pharmaceutical Co. Ltd. develops, manufactures and markets pharmaceuticals and medical products. The Group's principal activity is the manufacture and sale of pharmaceuticals, medical equipment and supplies, home care products, chemicals and animal health products. Pharmaceuticals (ethical drugs, OTC drugs, toilet goods) accounted for 91% of fiscal 2002 revenues and other operations (food additives, industrial chemicals, animal drugs, research and clinical reagents). It was founded in 1894 and was headquartered in Osaka, JP | Health Technology |
Prestwick Pharmaceuticals, Inc.
Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Health Technology |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
| Fujisawa Healthcare, Inc. | |
| Astellas Research Institute of America LLC | |
Auspex Pharmaceuticals, Inc.
 Auspex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Auspex Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of novel medicines for the treatment of orphan diseases. The company was founded by Sepehr Sarshar, Thomas G. Gant and Manouchehr M. Shahbaz on February 28, 2001 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- David Stamler
